SH3BP2 and gastrointestinal stromal tumor: We first assessed the expression of SH3BP2 and MITF in primary tumors of GIST patients with a clinically representative mutation spectrum of the disease: KIT mutations in exon 11 and PDGFRA mutations in exon 18, as well as KIT/PDGFRA wild‐type (WT).